HSS and Rothman Institute/Jefferson University Hospital to Participate in Clinical Trial for Elute's Antibiotic Loaded Bone Void Filler
Retrieved on:
Tuesday, November 30, 2021
Self-signed certificate, U.S. News & World Report, Investigational device exemption, Patient, IDE, NewYork-Presbyterian Hospital, CEO, Hip, Safety, US Foods, Technology, Rheumatology, Osteomyelitis, Elective surgery, News, Hospital for Special Surgery, SALT, Investigational New Drug, HSS, Clinical trial, Doctor of Philosophy, Education, Thomas Jefferson University, Food, Solution, The Hospital, Society, Physician, Rothman, Research, Clinical research, Health, Nursing, Weill Cornell Medicine, Organization, Hospital, FDA, EP, Tobramycin, Growth, Infection, Association, Javad Parvizi, Pharmaceutical industry, Dentistry, Antibiotics
HSS and Rothman will join a group of Elute's clinical partners focused on improving patient care and driving clinical value.
Key Points:
- HSS and Rothman will join a group of Elute's clinical partners focused on improving patient care and driving clinical value.
- "Rothman/Jefferson is happy to participate in this important clinical trial that will evaluate the role of an important and innovative product that offers the potential to help patients.
- Elute's lead product candidate isEP Granules with Tobramycin, a bone void filler that is designed to provide 8-week, delivery of an antibiotic while allowing growth of new bone.
- The joint replacement surgeons at Rothman Orthopaedics collectively perform over 17,000 hip and knee procedures each year in both an inpatient and outpatient capacity.